PRESS RELEASE published on 02/01/2024 at 22:10, 7 months 27 days ago Bausch Health Announces Board Refreshment Bausch Health Companies Inc. nominates two independent and diverse candidates, Christian A. Garcia and Frank D. Lee, for election to its Board of Directors. Russel C. Robertson and Thomas W. Ross, Sr. will retire from the Board, and the new nominees are expected to fill their roles. Bausch Health's 2024 Annual Meeting details will be included in the proxy statement Bausch Health Companies Inc. 2024 Annual Meeting Proxy Statement Board Refreshment Diverse Candidates
PRESS RELEASE published on 02/01/2024 at 14:00, 7 months 27 days ago Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22 Bausch Health Companies Inc. (NYSE/TSX:BHC) will release Q4 and full-year 2023 financial results on Feb. 22, 2024, followed by a conference call and webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update Financial Results Conference Call Bausch Health Companies Inc. Investor Relations Webcast
PRESS RELEASE published on 01/30/2024 at 14:00, 7 months 29 days ago CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S. Bausch Health and Ortho Dermatologics announced the U.S. launch of CABTREO Topical Gel, the first once-daily triple-combination topical treatment for acne vulgaris, approved by the FDA based on Phase 3 studies showing significant reductions in lesions Bausch Health Ortho Dermatologics CABTREO Topical Gel Acne Vulgaris
PRESS RELEASE published on 01/18/2024 at 22:50, 8 months 9 days ago CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China Bausch Health Companies Inc. and Solta Medical have announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA), marking a significant milestone for Solta Medical and opening up significant opportunities in the Chinese market. The approval represents a substantial achievement for the R&D and Regulatory Teams, signifying continued growth for the Thermage technology. The non-invasive treatment, which uses radiofrequency technology to tighten and improve the texture of the skin, has seen over two million treatments globally and is now set to continue its growth in China. The approval paves the way for delivering proven technology to the Chinese market and signifies a crucial breakthrough in the medical aesthetics market. Thermage FLX NMPA Approval Medical Aesthetics Market TR-4 Return Pad China
PRESS RELEASE published on 01/18/2024 at 14:00, 8 months 10 days ago Solta Medical’s Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China Bausch Health Companies Inc. and Solta Medical announce the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). This approval represents a significant breakthrough in one of the largest medical aesthetics markets, allowing the companies to continue the momentum of the growth of Thermage in China. The non-invasive treatment, Thermage, is a versatile and effective technology that can be used on all skin types and genders, delivering exceptional results for patients. For more information, visit www.bauschhealth.com and www.solta.com. Thermage FLX NMPA Approval Medical Aesthetics Market Non-invasive Treatment Bausch Health Companies
PRESS RELEASE published on 01/08/2024 at 06:00, 8 months 20 days ago Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals presented oral arguments at the U.S. Court of Appeals for the Federal Circuit regarding the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc. No ruling was issued following the oral arguments. The company continues to advocate for the safety of patients benefiting from XIFAXAN® (rifaximin) 550 mg tablets, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea. Salix Pharmaceuticals focuses on the prevention and treatment of gastrointestinal diseases for over 30 years and markets its products to U.S. health care providers. On the other hand, Bausch Health Companies Inc. is a global diversified pharmaceutical company with a mission to improve people's lives through various health care products, primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The news release contains forward-looking statements about Bausch Health's future performance and the appeal with respect to intellectual property. The actual results are subject to certain risks and uncertainties. For more information, visit www.bauschhealth.com and connect with them on Twitter and LinkedIn. Bausch Health Companies Inc. Salix Pharmaceuticals Gastrointestinal Diseases XIFAXAN Oral Arguments
PRESS RELEASE published on 12/21/2023 at 13:00, 9 months 7 days ago Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
PRESS RELEASE published on 12/18/2023 at 14:00, 9 months 10 days ago DUOBRII(TM) Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec’s Public Drug Plan
PRESS RELEASE published on 12/05/2023 at 14:00, 9 months 23 days ago Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day Salix Pharmaceuticals, Bausch Health Companies Inc., U.S. Pain Foundation, and IFFGD collaborate to establish the first annual Opioid-Induced Constipation (OIC) Awareness Day to raise awareness about the often-overlooked side effect of opioids and provide a platform for patients, caregivers, and healthcare providers to discuss and address OIC Healthcare Providers Chronic Pain Opioid-Induced Constipation Awareness Day Patient Advocacy
PRESS RELEASE published on 11/10/2023 at 14:00, 10 months 18 days ago The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis
Published on 09/28/2024 at 02:06, 20 hours 35 minutes ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 20 hours 41 minutes ago Quantum Biopharma Provides Corporate Update
Published on 09/28/2024 at 02:00, 20 hours 41 minutes ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 22 hours 31 minutes ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 8 hours 40 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 3 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 4 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 4 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 4 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 4 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 4 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024